• Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be safe and effective, for low- and middle-income countries in 2021

  • The expansion follows August’s announcement of up to 100 million doses to be delivered by the collaboration, bringing the total now to be delivered by the partnership to up to 200 million doses of COVID-19 vaccines, priced at a maximum of US$ 3 per dose, with an option to secure more

  • Dr Seth Berkley: “This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to the race for a COVID-19 vaccine”

Geneva, 29 September 2020 – A further collaboration among the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to an additional 100 million doses of safe and effective COVID-19 vaccines for low- and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.

This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement announced in August. This arrangement again provides an option to secure additional doses, potentially several times the 200 million dose total, if the COVAX Facility sees a need for it.

The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021. 

“This is vaccine manufacturing for the Global South, by the Global South, helping us to ensure no country is left behind when it comes to access to a COVID-19 vaccine,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “The momentum behind our effort to ensure global, equitable access to COVID-19 vaccines is really building. Last week we were able to announce the historic number of countries that are now signed up to the COVAX Facility, today we can announce further doses of safe, effective vaccines that will be reserved specifically for low- and middle-income countries. No country, rich or poor, should be left at the back of the queue when it comes to COVID-19 vaccines; this collaboration brings us another step closer to achieving this goal.”

The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and SII. 

“The collaboration further bolsters our fight against COVID-19! Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future COVID-19 vaccines to India and low- and middle-income countries in 2021,” said Adar Poonawalla, CEO of Serum Institute of India “At this stage, It is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that future vaccines reach the remotest parts of the world providing full immunization coverage in a bid to contain the spread of the pandemic.” 

The Gavi COVAX AMC, which is currently seeking at least US$2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. The Gavi Board has agreed upon the final list of 92 countries that will be supported by the Gavi COVAX AMC. Under the new collaboration, AstraZeneca’s candidate vaccine, if successful, will be available to 61 AMC-eligible countries. Novavax’s candidate, if successful, will be available to all 92 countries supported by the Gavi COVAX AMC. These countries align with SII’s licensing agreements with the two partners.

“This collaborative effort shows the capacity of the Access to COVID-19 Tools (ACT) Accelerator to bring together diverse partners to ensure a fair and effective response to this global crisis,” said Mark Suzman, CEO of the Bill & Melinda Gates Foundation.

The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, CEPI and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar.

Under the COVAX umbrella, Gavi is coordinating the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand. 

So far 75 higher-income economies have formally committed to join the Facility, in addition to the 92 low- and middle-income economies that are eligible for support from the Gavi COVAX AMC. 

The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million. This will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for low- and middle-income countries via Gavi’s COVAX AMC. 

The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will commit an additional 300 million doses of AstraZeneca’s candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help assure access to early doses for the most vulnerable on a truly global scale.


Media Contacts

James Fulker, Gavi
Phone: +41 79 429 55 05
Email: jfulker@gavi.org

Related content

18 October 2021

First Portuguese COVAX doses reach Senegal

As part of a pledge to share at least 5% of domestic supply of vaccines with its development partners, the first doses donated by Portugal through COVAX have reached Senegal.

11 October 2021

Vigne des Nations: 2020 vintage awarded to Gavi by Geneva Canton, for its action for global health

This Monday morning, 11 October, Mr Serge Dal Busco, President of the Council of State of Geneva, symbolically awarded the parcel of the Vigne des Nations to Gavi, the Vaccine Alliance. This recognition honours the commitment of this organisation…

11 October 2021

First Swiss-donated doses ship to Sierra Leone, as part of 4 million dose pledge

The first shipment of a Swiss donation of 4 million doses has arrived in Sierra Leone, with 24,000 doses of the AstraZeneca vaccine touching down in Freetown on 9 October 2021.

6 October 2021

Gavi, Unitaid and the Global Fund welcome WHO recommendation for world’s first malaria vaccine

WHO recommendation for wider use of the RTS,S malaria vaccine is largely based on data gathered during malaria vaccine pilots which took place in Kenya, Ghana and Malawi

6 October 2021

Gulf countries unite to support COVAX

Gulf Cooperation Council (GCC) countries have come together to support global equitable access to COVID-19 vaccines, with pledges now totalling US$ 221 million in funding pledges and US$ 50 million in in-kind support from all six Member States,…

29 September 2021

Gavi Board meets to discuss routine immunisation, COVAX’s 2022 strategy

The Gavi Board met yesterday to discuss the impact of the pandemic on routine immunisation and how COVAX can best support countries’ efforts to control the pandemic, as part of a broader consultative process to develop the 2022 COVAX strategy

29 September 2021

Gavi progress report shows resilience in childhood vaccinations despite impact of COVID-19 pandemic

In the face of a global pandemic, routine and childhood vaccination has held relatively strong, Gavi’s latest Annual Progress Report shows, with routine immunisations dropping 4% over the course of 2020.

23 September 2021

Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX

Leaders pledge financing, dose donations, support for country readiness and delivery and scale up of global manufacturing, to enable equitable access to COVID-19 vaccines.

22 September 2021

DFC and Citi Risk Management Solution Helps Gavi Strengthen the Foundations of the COVAX Facility

U.S. International Development Finance Corporation, in conjunction with Citi, launch risk management solution for COVAX Facility.

20 September 2021

Iceland renews commitment to global equitable access to vaccines: first doses arrive in Côte d’Ivoire

As part of a donation of 125,726 doses to COVAX, the first shipment of 35,700 doses of the AstraZeneca vaccine donated by Iceland has arrived in Côte d’Ivoire.

13 September 2021

Iraq receives first doses donated by Italy through COVAX

As part of its pledge to deliver 15 million doses of COVID-19 vaccines, the first doses donated by Italy have been delivered to Iraq, with more shipping to additional countries in the coming days.

8 September 2021

First delivery of German-donated COVID vaccines to COVAX land in Mauritania, with other deliveries to follow

Building on its pledge of EUR 1.62 billion to COVAX, the German government has donated the first batch of its pledge of 100 million doses of COVID-19 vaccines, the majority of which will be delivered via COVAX. 

8 September 2021

Joint COVAX statement on Supply Forecast for 2021 and early 2022

COVAX has already achieved significant progress: more than US$10 billion has been raised; legally-binding commitments for up to 4.5 billion doses of vaccine; 240 million doses have been delivered to 139 countries in just six months.

7 September 2021

Gavi funding boosts yellow fever diagnostics capacity across Africa

Gavi’s investment in initiative to boost yellow fever diagnostic capacity across Africa has ‘revolutionised’ diagnostics on the continent reducing the risk of future epidemics.

6 September 2021

First doses donated by Belgium through COVAX arrive to Armenia

As part of its pledge to deliver 4 million doses of COVID-19 vaccines, the first doses donated by Belgium have been delivered to Armenia.

2 September 2021

Canada donates doses through COVAX – Nigeria, Kenya and Niger to receive first doses

Three countries in Africa will receive the first Canadian-donated doses of the AstraZeneca vaccine – Nigeria (801,600 doses), Kenya (459,300) and Niger (100,800) – as part of an overall Canadian pledge of over 40 million doses to COVAX

30 August 2021

France donates 10 million doses to Africa through COVAX and AU

African Union Member States are to receive an additional 10 million doses of Astra Zeneca and Pfizer COVID-19 vaccines through COVAX and the Africa Vaccine Acquisition Trust (AVAT), thanks to a new arrangement with the French government and the…

26 August 2021

First Danish doses delivered through COVAX arrive in Algeria

The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August.

13 August 2021

UK-donated COVID-19 vaccine doses reach African countries

The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines…

6 August 2021

China pledges US$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries

The Government of the People’s Republic of China (China) has pledged US$100 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). The announcement, made at the International Forum on COVID-19 Vaccine Cooperation, hosted by China,…

5 August 2021

First doses donated by Spain through COVAX arrive to Peru, Guatemala, Paraguay and Nicaragua

As part of its pledge to deliver 22.5 million doses of COVID-19 vaccines, the first doses donated by Spain are arriving to countries in Latin America.

4 August 2021

New financing agreement boost for malaria vaccine

Gavi, MedAccess and GlaxoSmithKline join forces to guarantee continued production of the RTS,S antigen for the RTS,S/AS01e malaria vaccine.

30 July 2021

First Swedish doses delivered through COVAX

As part of a pledge to deliver at least three million doses of COVID-19 vaccines, the first doses donated by Sweden have been delivered to countries this week, with shipments arriving in Kyrgyzstan and Afghanistan

30 July 2021

First deliveries of Norway-donated COVID-19 vaccines to COVAX

Norway donates first doses to COVAX, with first shipments arriving in Nicaragua and Uganda on 30 July. In total, Norway has pledged 5 million doses to COVAX, as well as US$ 141 million in funding.

26 July 2021

COVAX and World Bank to Accelerate Vaccine Access for Developing Countries

COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing countries through a new financing mechanism that builds on Gavi’s newly designed AMC cost-sharing arrangement. This allows AMC countries to purchase doses beyond the…

23 July 2021

First doses donated by Japan to COVAX reach lower-income countries

The first COVID-19 vaccine doses donated by Japan to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) have been shipped, with first shipments set to arrive in Cambodia and Iran on Friday, 23 July, and Bangladesh on Saturday, 24 July.

16 July 2021

US-donated vaccine deliveries to Africa set to begin, with first deliveries planned to Burkina Faso, Djibouti, and Ethiopia

16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to…

12 July 2021

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against…

1 July 2021

6 million children benefitting from the first ever multi-antigen vaccination campaign

UNICEF, Gavi, the Vaccine Alliance and WHO have partnered with the Ministry of Health and Child Care to launch a new vaccine campaign introducing typhoid conjugate vaccine into the routine immunisation schedule across Zimbabwe. 

1 July 2021

Joint COVAX Statement on the equal recognition of vaccines

Geneva/New York/Oslo, 01 July 2021 – COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to…

30 June 2021

Indonesia introduces Pneumococcal Conjugate Vaccine (PCV) across the country

Jakarta/Geneva, 30 June 2021 – Up to 4.5 million children across Indonesia will be protected against the most common cause of severe pneumonia every year, after the introduction of Pneumococcal Conjugate Vaccine (PCV) into the country’s routine…

30 June 2021

Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX

Geneva, 30 June 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19. The agreement…

27 June 2021

US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras

Geneva, 27 June 2021 – Following announcements in recent weeks of donation pledges by the Biden-Harris Administration, COVAX is preparing to ship doses of COVID-19 vaccines donated to COVAX by the United States Government to protect at-risk…

24 June 2021

Gavi Board strengthens commitment to reaching the most vulnerable through routine immunisation and COVAX

Geneva, 25 June 2021 – The Board of Gavi, the Vaccine Alliance has made several decisions to strengthen the organisation’s commitment to protecting the most vulnerable everywhere – through routine immunisation, access to COVID-19 vaccines via the…

24 June 2021

Gavi and the Global Fund sign groundbreaking agreement with International Federation of Accountants to support in-country financial management

Geneva, 24 June 2021 – Global health leaders Gavi, the Vaccine Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria have joined forces with the International Federation of Accountants (IFAC) to contribute to, and support, the…

23 June 2021

What does COVAX’s latest supply forecast tell us?

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.

21 June 2021

Gavi allocates US$ 60 million for RBC GAM impact investment bond

Gavi is investing in the RBC Global Asset Management’s RBC Impact Bond Strategy, which supports measurable social and environmental progress.

18 June 2021

Republic of Korea pledges US$ 200 million to support lower-income economies through Gavi COVAX Advance Market Commitment

The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022

13 June 2021

G7 announces pledges of 870 million COVID-19 vaccine doses, of which at least half to be delivered by the end of 2021

COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.

10 June 2021

Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX

Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.

3 June 2021

Gavi welcomes U.S. allocation plan for vaccine dose-sharing – 19 million doses donated to COVAX in first tranche

Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…

2 June 2021

World leaders unite to commit to global equitable access for COVID-19 vaccines

The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…

31 May 2021

New Zealand transfers vaccine doses to COVAX – 6 Pacific nations first to benefit

Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.

27 May 2021

Call to action to equip COVAX to deliver 2 billion doses in 2021

Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.

21 May 2021

Global leaders renew their commitment to address urgency of COVID-19 pandemic

At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).

21 May 2021

Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX

The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.

18 May 2021

Go Give One campaign gives public the opportunity to support access to COVID-19 vaccines for lower-income countries

Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.

12 May 2021

Japan to host Gavi's COVAX Advance Market Commitment (AMC) Summit

Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.

10 May 2021

Corporations, charities and governments step up support for equitable COVID-19 vaccine access at Vax Live concert

The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State

6 May 2021

Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility

The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.

3 May 2021

Gavi signs agreement with Moderna to secure doses on behalf of COVAX Facility

The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…

26 April 2021

Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases

Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…

23 April 2021

France makes important vaccine dose donation to COVAX

Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…

15 April 2021

Global leaders rally to accelerate access to COVID-19 vaccines for lower-income countries

The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.

8 April 2021

COVAX reaches over 100 economies, 42 days after first international delivery

The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.

31 March 2021

Gavi and Save the Children form global partnership to immunise zero-dose and vulnerable children

The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.

29 March 2021

United States to host launch event for Gavi COVAX AMC 2021 investment opportunity

The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).

25 March 2021

COVAX updates participants on delivery delays for vaccines from Serum Institute of India (SII) and AstraZeneca

The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.

18 March 2021

Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and USAID announce innovative collaboration to support health supply chain leaders in low- and middle-income countries

A new partnership between three donor agencies jointly offers an updated version of the Strategic Training Executive Programme, known as STEP 2.0.

2 March 2021

COVAX publishes first round of allocations

Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…

1 March 2021

First COVID-19 COVAX vaccine doses administered in Africa

Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers

24 February 2021

COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global roll-out

COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.

22 February 2021

No-fault compensation programme for COVID-19 vaccines is a world first

New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.

19 February 2021

G7 backs Gavi's COVAX Advance Market Commitment to boost COVID-19 vaccines in world’s poorest countries

Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.

18 February 2021

Gavi signs memorandum of understanding with Novavax on behalf of COVAX Facility

The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.

16 February 2021

COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine

Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…

8 February 2021

COVAX Statement on New Variants of SARS-CoV-2

The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.

3 February 2021

COVAX publishes first interim distribution forecast

Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…

22 January 2021

COVAX announces new agreement, plans for first deliveries

COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.

12 January 2021

500,000 doses of Ebola vaccine to be made available to countries for outbreak response

A Gavi-funded global emergency stockpile of Ebola vaccines will be accessible to all countries following a procurement process concluded by UNICEF

28 December 2020

Gavi welcomes final approval of U.S. support for global immunisation in Year-End Omnibus and COVID Supplemental Package

The United States has approved US$ 4 billion for Gavi, the Vaccine Alliance to ensure lower-income economies have equitable access to safe and effective COVID-19 vaccines on the same urgent timeline as wealthier countries.

18 December 2020

COVAX announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.

17 December 2020

Gavi Board approves new push to reach unvaccinated children worldwide

Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.

15 December 2020

Team Europe contributes €500 million to COVAX initiative to provide one billion COVID-19 vaccine doses for low- and middle-income countries

High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.

24 November 2020

Gavi and IOM join forces to improve immunisation coverage for migrants

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

24 November 2020

Gavi statement on AstraZeneca/Oxford interim efficacy data

Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.

13 November 2020

COVAX Facility convenes first meeting of COVAX AMC engagement group

The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.

13 November 2020

Over US$ 2 billion raised to support equitable access to COVID vaccines with additional US$ 5 billion needed in 2021

The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

3 November 2020

COVAX Facility convenes first meeting of COVAX Shareholders Council

The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.

30 October 2020

COVAX welcomes appointment of civil society representatives

As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…

28 October 2020

Gavi signs statement of intent to procure 200 million doses of Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility

Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.

27 October 2020

Myanmar introduces cervical cancer vaccine nationally, despite COVID-19 challenges

Around 450,000 girls aged 9-10 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia.

8 October 2020

Japan pledges US$ 130 million to support global access to COVID-19 vaccines

Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.

6 October 2020

Countries pledge nearly US$ 1 billion to support equitable access to COVID-19 vaccines

The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

1 October 2020

Gavi to provide US$ 150 million to support low- and middle-income countries’ readiness to deliver COVID-19 vaccines

The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment

29 September 2020

New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries

Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…

29 September 2020

José Manuel Barroso named as new Chair of the Gavi Board

Gavi Board unanimously approves the selection of former Prime Minister of Portugal and President of the European Commission José Manuel Barroso as its new Chair

21 September 2020

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility

64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days

28 August 2020

Australia commits AU$ 80 million to guarantee access to COVID-19 vaccines for all

The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations

24 August 2020

172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility

Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries

19 August 2020

Call for applications: COVAX seeks civil society representatives to contribute to ensuring equitable global access to COVID-19 vaccines

CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.

7 August 2020

Up to 100 million COVID-19 vaccine doses to be made available for low- and middle-income countries as early as 2021

New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…

31 July 2020

92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC

Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.

27 July 2020

Gavi helps immunise 65 million children in 2019, though COVID-19 puts progress under pressure

New analysis of WHO/UNICEF data by Gavi, the Vaccine Alliance, shows the gap in vaccine coverage between Gavi-supported lower-income countries and wealthier countries has shrunk to record lows

15 July 2020

More than 150 countries engaged in COVID-19 vaccine global access facility

Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)

3 July 2020

New private sector commitments to fund access to future COVID-19 vaccines announced at international pledging summit

Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

26 June 2020

Gavi Board calls for global access to COVID-19 vaccines

Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible

25 June 2020

First-of-its-kind vaccine agreement helps end Ebola outbreak in eastern DRC

DRC government and WHO declare over the long-running Ebola outbreak in North Kivu, South Kivu and Ituri provinces after more than 50 days without a case.

24 June 2020

Gavi a top performer in leading transparency index

The Vaccine Alliance ranked in the highest ‘Very good’ category out of 47 international development organisations assessed in the 2020 Aid Transparency Index

23 June 2020

DRC recognised for its immunisation efforts

The Government of the Democratic Republic of the Congo is doubling its vaccine funding

16 June 2020

Pneumonia vaccine price drops dramatically for lower-income countries thanks to the Gavi Pneumococcal AMC

New supply agreement between UNICEF and Serum Institute of India (SII) makes pneumococcal conjugate vaccine (PCV) available at US$2.00 per dose, a 43% reduction from the Gavi price at the start of the AMC

4 June 2020

World leaders make historic commitments to provide equal access to vaccines for all

The Global Vaccine Summit, hosted by the UK, raises US$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300m children and support the global fight against COVID-19.

4 June 2020

Gavi launches innovative financing mechanism for access to COVID-19 vaccines

Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.

3 June 2020

HPV vaccine manufacturers commit to provide enough supply to immunise at least 84 million girls in Gavi countries

On the eve of the Global Vaccine Summit 2020, five manufacturers commit to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world.

3 June 2020

Private sector partners strengthen Gavi programmes with more than US$ 70 million in contributions

The commitments build on the potency of public private partnerships, which have contributed to Gavi’s success.

1 June 2020

Switzerland commits CHF 30 million to Gavi

Contribution will go towards Gavi’s efforts to deliver life-saving vaccines to children in the world’s poorest countries in 2021-2025 strategic period.

1 June 2020

Italy deepens support for Gavi with €150 million IFFIm pledge

Pledge follows €120 million in direct funding to Gavi Italy announced at last month’s Coronavirus Global Response pledging conference.

1 June 2020

Gavi receives US$ 5 million from The Rockefeller Foundation

Gavi receives US$ 5 million from the Rockefeller Foundation to support health workers facing COVID-19 pandemic 

1 June 2020

The UPS Foundation commits US$ 3 million to Gavi

UPS partnership with Gavi builds on successful efforts to expand and improve vaccine delivery in Uganda and some of the world’s most underserved communities.

1 June 2020

New donor Greece pledges €1.5 million to Gavi COVID response

New funding for Gavi to support lower-income countries’ response to the COVID-19 pandemic, including supporting health systems.

26 May 2020

New Zealand announces NZ$ 7 million pledge to Vaccine Alliance

Funding will support the response to the COVID-19 pandemic in lower-income countries as well as the vaccination of thousands of children in vulnerable Pacific nations.

22 May 2020

At least 80 million children at risk of disease as COVID-19 disrupts vaccination efforts, warn Gavi, WHO and UNICEF

Agencies call for joint effort to safely deliver routine immunization and proceed with vaccination campaigns against deadly vaccine-preventable diseases.

12 May 2020

Canada commits CAD 600 million to Gavi

Canada’s contribution will go towards Gavi’s efforts to deliver life-saving vaccines to children in the world’s poorest countries in 2021-2025 strategic period.

11 May 2020

Spain pledges new support to Gavi

Funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.

6 May 2020

Italy pledges new support to Gavi

Funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.

5 May 2020

Countries pledge new support to Gavi

The funding will help immunise 300 million children over the next five years, saving up to 8 million lives, as well as support universal access to COVID-19 vaccines.

4 May 2020

Norway increases commitment to immunisation for the most vulnerable, pledges USD 1 billion to Gavi

Funding will help Gavi protect the most vulnerable, particularly children, against a range of infectious diseases.

29 April 2020

Gavi welcomes UK funding pledge

Funding will support Gavi’s response to COVID-19 along with efforts to vaccinate 300 million children across the developing world, saving up to 8 million lives.

29 April 2020

Gavi welcomes US$ 10 million contribution from TikTok

Short video platform pledges to support Gavi’s life-saving immunisation programmes and future deployment of COVID-19 vaccines.

28 April 2020

COVID-19: Gavi and UNICEF to secure equipment and diagnostics for lower-income countries

As part of Gavi’s work supporting lower-income countries’ response to COVID-19, the Alliance is providing US$ 40 million to UNICEF to secure supplies of personal protective equipment (PPE) and diagnostics for 58 countries.

24 April 2020

Gavi and global health actors collaborate to accelerate COVID-19 technologies for all

Goal of new global collaboration is to make COVID-19 diagnostics, therapeutics and vaccines available to everybody that needs them as quickly as possible.

17 April 2020

Saudi Arabia pledges US$ 150 million to Gavi COVID response

Pledge follows G20 commitment to provide immediate resources to Gavi.

17 April 2020

Reed Hastings and Patty Quillin support Gavi with US$ 30 million donation

Cash donation supports the Alliance’s response to COVID-19 and helps protect the world against new outbreaks of other infectious diseases.

3 April 2020

COVID-19: massive impact on lower-income countries threatens more disease outbreaks

At least 13.5 million people to miss out on vaccinations due to postponement of campaigns and interruptions in routine vaccinations, with millions more likely to follow.

20 May 2019

72nd World Health Assembly

With senior health officials setting the annual direction for the World Health Organization this week, multiple health challenges and considerations vie for attention amidst a packed agenda. Find out how Gavi helps ensure that immunisation is…

5 February 2018

Study: vaccines prevent not just disease, but also poverty

New study shows that immunisation in the world’s poorest countries is set to save millions from one of the primary causes of extreme poverty: health expenses

20 January 2016

Ebola vaccine purchasing commitment from Gavi to prepare for future outbreaks

Agreement will help push vaccine towards regulatory approval.

27 January 2015

World leaders make record-breaking commitment to protect poorest children with vaccines

Support puts Gavi, the Vaccine Alliance on the path to immunise a further 300 million children and save up to 6 million more lives.

11 December 2014

Gavi commits to purchasing Ebola vaccine for affected countries

Vaccine Alliance ready to begin procurement as soon as WHO recommends a vaccine for use.

30 March 2005

Barcelona Declaration

Subscribe to our newsletter